Literature DB >> 25409753

Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro.

Maria Antonia Frassanito1, Simona Ruggieri2, Vanessa Desantis3, Lucia Di Marzo3, Patrizia Leone3, Vito Racanelli3, Ruggiero Fumarulo1, Franco Dammacco3, Angelo Vacca3.   

Abstract

Regulatory T cells (Tregs) are essential for maintenance of self-tolerance; however, tumor cells can exploit the tolerance to escape the immune system. We investigated the Tregs frequency in patients with multiple myeloma (MM) and in those with monoclonal gammopathy of undetermined significance (MGUS), and found that CD4(+) FoxP3(+) and CD8(+) FoxP3(+) Tregs were significantly increased in patients with MM and correlated with the active phase. Both Tregs subsets were expanded in cocultures of CD3(+) lymphocytes and fresh CD138(+) MM plasma cells or RPMI8226 and U266 cell lines and functioned as natural (n) and inducible (i) Tregs insofar as they inhibited the proliferation of stimulated CD3 lymphocytes via contact-dependent and contact-independent pathways. Induction of Tregs by MM plasma cells required a contact-dependent pathway, implying antigen recognition by T cells. MM plasma cells acted as immature and tolerogenic antigen-presenting cells (APCs), in that they displayed low CD80/CD86 expression associated with a phagocytic activity. By acting as immature APCs, MM plasma cells plausibly expand (n)Tregs and (i)Tregs both through conversion of CD3(+) FoxP3(-) into CD3(+) FoxP3(+) T cells and proliferation of CD3(+) FoxP3(+) T cells, which may suppress the anti-MM immune response.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antigen-presenting cells; multiple myeloma; regulatory T cells

Mesh:

Substances:

Year:  2015        PMID: 25409753     DOI: 10.1111/ejh.12481

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Authors:  Xiaoyan Feng; Li Zhang; Chirag Acharya; Gang An; Kenneth Wen; Lugui Qiu; Nikhil C Munshi; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-03-01       Impact factor: 12.531

2.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 3.  Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.

Authors:  Jonas Schwestermann; Andrej Besse; Christoph Driessen; Lenka Besse
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 4.  Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression.

Authors:  Ilaria Saltarella; Aurelia Lamanuzzi; Benedetta Apollonio; Vanessa Desantis; Giulia Bartoli; Angelo Vacca; Maria Antonia Frassanito
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

5.  Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.

Authors:  Karel Fostier; Jo Caers; Nathalie Meuleman; Katrijn Broos; Jurgen Corthals; Kris Thielemans; Rik Schots; Brenda De Keersmaecker
Journal:  Oncotarget       Date:  2018-04-17

6.  Increased circulating CD4+FOXP3+ T cells associate with early relapse following autologous hematopoietic stem cell transplantation in multiple myeloma patients.

Authors:  Egor V Batorov; Marina A Tikhonova; Natalia V Pronkina; Irina V Kryuchkova; Vera V Sergeevicheva; Svetlana A Sizikova; Galina Y Ushakova; Tatiana A Aristova; Dariya S Batorova; Elena V Menyaeva; Andrey V Gilevich; Ekaterina Y Shevela; Alexander A Ostanin; Elena R Chernykh
Journal:  Oncotarget       Date:  2018-06-05

Review 7.  Actors on the Scene: Immune Cells in the Myeloma Niche.

Authors:  Patrizia Leone; Antonio Giovanni Solimando; Eleonora Malerba; Rossella Fasano; Alessio Buonavoglia; Fabrizio Pappagallo; Valli De Re; Antonella Argentiero; Nicola Silvestris; Angelo Vacca; Vito Racanelli
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

8.  Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results.

Authors:  Rita Fazzi; Iacopo Petrini; Nicola Giuliani; Riccardo Morganti; Giovanni Carulli; Benedetta Dalla Palma; Laura Notarfranchi; Sara Galimberti; Gabriele Buda
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.